Elicio Therapeutics, Inc. (ELTX) stock
ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.59+0.16 (+11.19%)
Close on Nov 18, 2026Market cap $41.79MP/E –Yield –
Elicio Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Elicio Therapeutics's revenue for the twelve months ending Mar 31, 2023 was $653.00K, down 97.8% year over year. For fiscal 2022 it was $2.30M, down 91.9% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2.30M | -91.9% |
| FY2021 | Dec 31, 2021 | $28.31M | +883.1% |
| FY2020 | Dec 31, 2020 | $2.88M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $0 | -100.0% |
| Q2 FY2022 | Jun 30, 2022 | $653.00K | +20.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.65M | +344.2% |
| Q4 FY2021 | Dec 31, 2021 | $25.94M | +5551.6% |
| Q3 FY2021 | Sep 30, 2021 | $1.46M | +76.5% |
| Q2 FY2021 | Jun 30, 2021 | $540.00K | -25.9% |
| Q1 FY2021 | Mar 31, 2021 | $371.00K | -57.1% |
| Q4 FY2020 | Dec 31, 2020 | $459.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $827.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $729.00K | – |
| Q1 FY2020 | Mar 31, 2020 | $865.00K | – |
See a number that looks wrong?